Please login to the form below

Not currently logged in
Email:
Password:

financial report

This page shows the latest financial report news and features for those working in and with pharma, biotech and healthcare.

Novartis claims first CAR-T approval, setting $475k price tag

Novartis claims first CAR-T approval, setting $475k price tag

A report in the Financial Times suggests the cost of goods for Kymriah comes in at around $200, 000 per patient.

Latest news

More from news
Approximately 1 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    According to a Financial Times report, this deal comes only months after BD at an analyst briefing stated it was seeking to reduce its leverage to three times annual cash flow. ... the company and improve its financial results ready for Bain/Cinven’s

  • Pharma deals during September 2013 Pharma deals during September 2013

    As is customary this month's report focuses on deals with disclosed financial terms.

  • Pharma deals during August 2013 Pharma deals during August 2013

    As is customary this month's report focuses on deals with disclosed financial terms. ... A minor diversion. And finally deviating from our customary practice, a mention of a deal with undisclosed financial terms, namely the three year, preclinical

  • Country report: The healthcare market in South Korea Country report: The healthcare market in South Korea

    according to the JMAJ report 'The South Korean Health Care System', from 2009. ... 9. Bayer. 10 . Roche. Source: Invest Korea (each company's financial report [2008]); Daily Pharma News (April 7, 2008) Note: year-on-year basis.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics